GKOS Glaukos Corporation
Glaukos Corporation (GKOS) is expected to report earnings on October 28, 2026, after the market close. The consensus earnings estimate is a loss of $0.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.4% since its last earnings release on July 29, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Glaukos Corporation
Glaukos is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
Sector
Healthcare
Industry
Medical Appliances/Equipment